BRCA1 and neoplasm: It appears that the use of PARPi might not be limited to tumors with mutation in the BRCA1/2 tumor suppressors since Zoumpoulidou et al. [23] documented highly penetrant PARPi hypersensitivity following mutations of RB1 (a negative regulator of the cell cycle).